UoH startup BioVaram partners with Japan’s Teijin for regenerative medicine

Hyderabad: BioVaram, a biotech startup incubated at the University of Hyderabad’s ASPIRE-BioNEST, has signed a strategic partnership with Japan’s Teijin Limited to advance regenerative medicine initiatives between India and Japan.

Partnership to focus on product approvals and global market entry

As part of the agreement, BioVaram and Teijin will jointly pursue regulatory approvals and commercialization of Teijin’s cardiovascular repair patch, SYNFOLIUMⓇ, and regenerative medicine products developed by J-TEC in India. Simultaneously, Teijin will support BioVaram’s efforts to develop and introduce its technologies such as exosome-based diagnostics, extracellular matrix (ECM) mimics, and bio-derived materials into the Japanese market.

Dr. Takayuki Nakano, Mission Executive at Teijin, stated that the collaboration represents a key move in Teijin’s global expansion plan. BioVaram CEO Dr. Jaganmohan Reddy noted that the alliance would help propel India’s biotech innovations onto the global stage.

Recognized startup backed by national and private funding

Founded in 2020, BioVaram has received funding from the ASPIRE Seed Fund, BIRAC BIG, and private investors. The startup was recently named among the Top 5 Startups at BioAsia 2024. Teijin, founded in 1918, operates through 170 subsidiaries worldwide and has set a target of achieving JPY 20 billion in regenerative medicine sales by 2030.